Literature DB >> 15968104

The 5T2MM murine model of multiple myeloma: maintenance and analysis.

Karin Vanderkerken1, Kewal Asosingh, Angelo Willems, Hendrik De Raeve, Pedro Couck, Frans Gorus, Peter Croucher, Ben Van Camp.   

Abstract

Multiple myeloma is a B-cell neoplasm characterized by the monoclonal proliferation of plasma cells in the bone marrow, the development of osteolytic lesions, and the induction of angiogenesis. These different processes require three-dimensional interactions, with both humoral and cellular contacts. The 5TMM models are suitable to study these interactions. These are murine models that originate from spontaneously developed myeloma in elderly mice. They are propagated by in vivo transfer of the myeloma cells into young syngeneic mice. We report methods involving the maintenance of the 5T2MM model and the quantification of tumor burden (by determining serum paraprotein concentration and plasmacytosis), assessment of bone lesions, and quantification of angiogenesis. The combination of these different techniques in these models not only helps in unraveling basic biological processes but also in the testing of potentially new therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968104     DOI: 10.1385/1-59259-916-8:191

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  9 in total

1.  Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Authors:  Haneen Nur; Karel Fostier; Sandrine Aspeslagh; Wim Renmans; Elisabeth Bertrand; Xavier Leleu; Mérédis Favreau; Karine Breckpot; Rik Schots; Marc De Waele; Els Van Valckenborgh; Elke De Bruyne; Thierry Facon; Dirk Elewaut; Karin Vanderkerken; Eline Menu
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 2.  Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma.

Authors:  Helena Jernberg-Wiklund; Kenneth Nilsson
Journal:  Ups J Med Sci       Date:  2012-02-21       Impact factor: 2.384

3.  Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.

Authors:  Andrei A Postnov; Henk Rozemuller; Viviene Verwey; Henk Lokhorst; Nora De Clerck; Anton C Martens
Journal:  Calcif Tissue Int       Date:  2009-10-09       Impact factor: 4.333

4.  Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.

Authors:  Clive Henry Buckle; Evy De Leenheer; Michelle Anne Lawson; Kwee Yong; Neil Rabin; Mark Perry; Karen Vanderkerken; Peter Ian Croucher
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

5.  Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.

Authors:  Simone S Riedel; Anja Mottok; Christian Brede; Carina A Bäuerlein; Ana-Laura Jordán Garrote; Miriam Ritz; Katharina Mattenheimer; Andreas Rosenwald; Hermann Einsele; Bjarne Bogen; Andreas Beilhack
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 6.  Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo.

Authors:  Maurizio Zangari; Hanna Yoo; Ik Jae Shin; Donghoon Yoon; Larry J Suva
Journal:  J Bone Oncol       Date:  2018-02-23       Impact factor: 4.072

7.  The genetic landscape of 5T models for multiple myeloma.

Authors:  Ken Maes; Bram Boeckx; Philip Vlummens; Kim De Veirman; Eline Menu; Karin Vanderkerken; Diether Lambrechts; Elke De Bruyne
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

8.  Differential Pain-Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma.

Authors:  Marta Diaz-delCastillo; Danna Kamstrup; Rikke Brix Olsen; Rie Bager Hansen; Thomas Pembridge; Brigita Simanskaite; Juan Miguel Jimenez-Andrade; Michelle A Lawson; Anne-Marie Heegaard
Journal:  JBMR Plus       Date:  2019-12-30

9.  Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.

Authors:  J Caers; E Menu; H De Raeve; D Lepage; E Van Valckenborgh; B Van Camp; E Alvarez; K Vanderkerken
Journal:  Br J Cancer       Date:  2008-06-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.